Bluesky Explorer

#Haemonetics

Latest posts tagged with #Haemonetics on Bluesky

Trending

#MJF Tribute #WBC #Javier Bardem #Marty Supreme #Andrade #Jessie Buckley #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace #MJF Tribute #WBC #Javier Bardem #Marty Supreme #Andrade #Jessie Buckley #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace

Posts tagged #Haemonetics

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Preview

Haemonetics Achieves FDA Clearance for Advanced Plasma Collection System NexSys® PCS with Innovative Technology Haemonetics Corporation proudly announces FDA clearance for its NexSys PCS system, enhancing plasma collection with advanced technology and improved donor experience.

Haemonetics Achieves FDA Clearance for Advanced Plasma Collection System NexSys® PCS with Innovative Technology #United_States #Boston #Haemonetics #NexSys_PCS #Persona_PLUS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Preview

Haemonetics Corporation CEO to Engage with Investors at the Upcoming Raymond James Conference Chris Simon, the CEO of Haemonetics Corporation, is set to participate in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026, discussing key insights with investors.

Haemonetics Corporation CEO to Engage with Investors at the Upcoming Raymond James Conference #United_States #Boston #Haemonetics #Investors_Conference #Chris_Simon

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Preview

Haemonetics Corporation Releases Financial Results for Q3 of Fiscal Year 2026 Haemonetics Corporation has released its financial results for the third quarter of fiscal 2026. A conference call will be held to discuss details and insights.

Haemonetics Corporation Releases Financial Results for Q3 of Fiscal Year 2026 #USA #Boston #financial_results #Investor_Relations #Haemonetics

0 0 0 0

@emergingtechnews.bsky.social

1 month ago

Acquisitions: #CareRev < #InteltCare; #CorpAcq > #Nonwovenn; #GlobalPayments > #Worldpay; #Haemonetics > #VivasureMedical; #InherentGroup > #Inovacom; #Whitevision > #DocumentLogistix

Agreed Acquisitions: #OpenAI > #Convogo; #Snowflake > #Observe; #Teneo > #ClarityPartners

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Preview

EQT Life Sciences Completes Vivasure Medical Sale to Haemonetics EQT Life Sciences has exited Vivasure Medical through a transaction with Haemonetics, enhancing its closure technology offerings with PerQseal Elite.

EQT Life Sciences Completes Vivasure Medical Sale to Haemonetics #None #Haemonetics #EQT_Life_Sciences #Vivasure_Medical

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Preview

Haemonetics Expands Portfolio through Acquisition of Vivasure Medical Limited Haemonetics Corporation has completed its acquisition of Vivasure Medical, enhancing its innovative solutions in patient care through advanced closure technologies.

Haemonetics Expands Portfolio through Acquisition of Vivasure Medical Limited #United_States #Boston #Haemonetics #Vivasure_Medical #PerQseal

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Preview

Haemonetics Corporation Reveals Strong Q2 FY2026 Financial Outcomes for Investors and Stakeholders Haemonetics Corporation has disclosed its financial performance for the second quarter of fiscal year 2026. Aimed at informing investors, the results showcase the company's commitment to healthcare innovation.

Haemonetics Corporation Reveals Strong Q2 FY2026 Financial Outcomes for Investors and Stakeholders #United_States #Boston #financial_results #Haemonetics #NYSE:_HAE

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Preview

Haemonetics Releases Financial Results for First Quarter of Fiscal Year 2026 Haemonetics Corporation has shared its financial results for the first quarter of fiscal year 2026, highlighting key performance indicators and next steps.

Haemonetics Releases Financial Results for First Quarter of Fiscal Year 2026 #United_States #Boston #earnings_report #Haemonetics #fiscal_year_2026

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

8 months ago

Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes Investing.com -- Citi analysts have taken action on two U.S. MedTech names, upgrading Haemonetics (NYSE:HAE) to Buy from Neutral, while downgrading Tandem Diabetes Care (NASDAQ:TNDM) to Sell/High Risk from Neutral/High Risk, citing diverging prospects in the second half of 2025. On Haemonetics, Citi sees a more derisked outlook following the company’s fiscal 2026 guidance. “With HAE FY26 guidance clearing the hurdle, the path forward is more derisked as Plasma share gains are baked into contracts,” analysts wrote. Citi now expects high single-digit core revenue growth (ex-CSL) and margin expansion to deliver high-teens EPS growth, raising its price target to $90 from $71. In contrast, Tandem is said to face mounting headwinds. “While the 2Q25 delivery will be imperative, commentary on competition and the impact of potential competitive bidding will be top of mind,” Citi noted. The firm believes these factors will keep the stock under pressure and downgraded TNDM to Sell, slashing its price target from $24 to $14. Citi’s broader outlook on the MedTech sector remains constructive. While tariff-related uncertainty continues to cloud guidance, analysts are embracing a “return to fundamentals with several catalysts providing momentum in 2H25+.” Notably, the bank continues to favor BSX and EW as Top Picks and initiated a positive catalyst watch on GE Healthcare and Intuitive Surgical (NASDAQ:ISRG). Despite macro volatility, Citi said the sector is outperforming its healthcare peers, noting the S&P Equipment & Supplies Index is up 7.2% year-to-date versus Biotechnology at 5.7% and Pharmaceuticals down 3.7%. With ISRG making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ISRG alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ISRG, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ISRG poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #MedTech #Investing #HealthcareStocks #Haemonetics #TandemDiabetes

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Preview

Haemonetics Corporation Strengthens Leadership Team with Key Appointments Haemonetics Corporation announces significant changes in its leadership team, appointing Frank Chan as COO and promoting Roy Galvin to CCO.

Haemonetics Corporation Strengthens Leadership Team with Key Appointments #USA #Boston #Haemonetics #Frank_Chan #Roy_Galvin

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Preview

Haemonetics Corporation Reports Third Quarter Earnings for Fiscal Year 2025 Haemonetics Corporation has released its financial results for the third quarter of FY2025, revealing trends in medical technology and investor insights.

Haemonetics Corporation Reports Third Quarter Earnings for Fiscal Year 2025 #USA #Boston #medical_technology #earnings_report #Haemonetics

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Preview

Haemonetics Finalizes Strategic Sale of Whole Blood Assets to GVS, S.p.A Haemonetics Corporation has finalized the sale of its whole blood assets to GVS, S.p.A for a total of up to $67.8 million. This transaction aims to focus on growth initiatives in medical technology.

Haemonetics Finalizes Strategic Sale of Whole Blood Assets to GVS, S.p.A #United_States #Boston #Haemonetics #GVS #blood_collection

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Preview

Haemonetics Completes Deal to Sell Whole Blood Assets to GVS for Up to $67.1 Million Haemonetics has announced the sale of its whole blood assets to GVS, S.p.A for $67.1 million, streamlining its focus on medical solutions and patient care.

Haemonetics Completes Deal to Sell Whole Blood Assets to GVS for Up to $67.1 Million #United_States #Boston #Haemonetics #GVS #blood_collection

0 0 0 0